ESMO 2023: Highlights and analysis

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Patient advocacy – the right communication

Hope vs Hype of evidence interpretation

Haemato-oncological Cancers

Gynaecological Cancers

GI cancers

Shared decision making (Patient-oncologist)

Engaging with policy makers